Hepatic α1‐antitrypsin mRNA content in cirrhosis with normal and abnormal protease inhibitor phenotypes

Sarah J Schwarzenberg, Harvey L. Sharp, Robin D. Manthei, Steven Seelig

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We quantitated α1‐antitrypsin mRNA in normal, α1‐antitrypsin‐deficient cirrhotic and biliary cirrhotic livers using two‐dimensional electrophoretograms of [35S] methionine‐labeled translational products of total hepatic RNA and RNA/DNA hybridization. α1‐antitrypsin precursor product was identified by immunoprecipitation. The relative abundance of α1‐antitrypsin product from normal (0.989 ± 0.197), cirrhotic (0.956 ± 0.062) and α1‐antitrypsin deficient (0.818 ± 0.12) livers was not significantly different. Although (RNA/DNA) was decreased in the PiZZ cirrhotic livers compared to normal (0.56 ± 0.045 vs. 0.95 ± 0.225), it equaled that found in the PiM cirrhotic livers (0.56 ± 0.055). The concentration of α1‐antitrypsin mRNA [relative abundance × (RNA/DNA)], while decreased in PiZZ compared to normal liver, is thus no different in PiZZ cirrhotics than in PiM cirrhotics. We confirmed this observation by quantitation of the α1‐antitrypsin mRNA using an α1‐antitrypsin genomic probe. By RNA/DNA hybridization, α1‐antitrypsin mRNA was equal in PiM cirrhotic and PiZZ cirrhotic (38.48 ± 4.5 vs. 31.93 ± 2.1), but significantly decreased from noncirrhotic PiM liver (58.36 ± 12.7). We conclude that α1‐antitrypsin mRNA is decreased in cirrhosis of any etiology, and this decrease appears to represent a general response of the liver to injury. Since the decreased α1‐antitrypsin mRNA in PiM cirrhotics is associated with normal serum α1‐antitrypsin levels, it is unlikely that the decreased α1‐antitrypsin mRNA in PiZZ cirrhotics accounts for their decreased serum levels.

Original languageEnglish (US)
Pages (from-to)1252-1258
Number of pages7
JournalHepatology
Volume6
Issue number6
DOIs
StatePublished - Jan 1 1986

Fingerprint

Protease Inhibitors
Fibrosis
Phenotype
Messenger RNA
Liver
RNA
DNA
Serum
Immunoprecipitation
Wounds and Injuries

Cite this

Hepatic α1‐antitrypsin mRNA content in cirrhosis with normal and abnormal protease inhibitor phenotypes. / Schwarzenberg, Sarah J; Sharp, Harvey L.; Manthei, Robin D.; Seelig, Steven.

In: Hepatology, Vol. 6, No. 6, 01.01.1986, p. 1252-1258.

Research output: Contribution to journalArticle

Schwarzenberg, Sarah J ; Sharp, Harvey L. ; Manthei, Robin D. ; Seelig, Steven. / Hepatic α1‐antitrypsin mRNA content in cirrhosis with normal and abnormal protease inhibitor phenotypes. In: Hepatology. 1986 ; Vol. 6, No. 6. pp. 1252-1258.
@article{6deca21e2f8f48d4a465fd9267c7ee73,
title = "Hepatic α1‐antitrypsin mRNA content in cirrhosis with normal and abnormal protease inhibitor phenotypes",
abstract = "We quantitated α1‐antitrypsin mRNA in normal, α1‐antitrypsin‐deficient cirrhotic and biliary cirrhotic livers using two‐dimensional electrophoretograms of [35S] methionine‐labeled translational products of total hepatic RNA and RNA/DNA hybridization. α1‐antitrypsin precursor product was identified by immunoprecipitation. The relative abundance of α1‐antitrypsin product from normal (0.989 ± 0.197), cirrhotic (0.956 ± 0.062) and α1‐antitrypsin deficient (0.818 ± 0.12) livers was not significantly different. Although (RNA/DNA) was decreased in the PiZZ cirrhotic livers compared to normal (0.56 ± 0.045 vs. 0.95 ± 0.225), it equaled that found in the PiM cirrhotic livers (0.56 ± 0.055). The concentration of α1‐antitrypsin mRNA [relative abundance × (RNA/DNA)], while decreased in PiZZ compared to normal liver, is thus no different in PiZZ cirrhotics than in PiM cirrhotics. We confirmed this observation by quantitation of the α1‐antitrypsin mRNA using an α1‐antitrypsin genomic probe. By RNA/DNA hybridization, α1‐antitrypsin mRNA was equal in PiM cirrhotic and PiZZ cirrhotic (38.48 ± 4.5 vs. 31.93 ± 2.1), but significantly decreased from noncirrhotic PiM liver (58.36 ± 12.7). We conclude that α1‐antitrypsin mRNA is decreased in cirrhosis of any etiology, and this decrease appears to represent a general response of the liver to injury. Since the decreased α1‐antitrypsin mRNA in PiM cirrhotics is associated with normal serum α1‐antitrypsin levels, it is unlikely that the decreased α1‐antitrypsin mRNA in PiZZ cirrhotics accounts for their decreased serum levels.",
author = "Schwarzenberg, {Sarah J} and Sharp, {Harvey L.} and Manthei, {Robin D.} and Steven Seelig",
year = "1986",
month = "1",
day = "1",
doi = "10.1002/hep.1840060605",
language = "English (US)",
volume = "6",
pages = "1252--1258",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Hepatic α1‐antitrypsin mRNA content in cirrhosis with normal and abnormal protease inhibitor phenotypes

AU - Schwarzenberg, Sarah J

AU - Sharp, Harvey L.

AU - Manthei, Robin D.

AU - Seelig, Steven

PY - 1986/1/1

Y1 - 1986/1/1

N2 - We quantitated α1‐antitrypsin mRNA in normal, α1‐antitrypsin‐deficient cirrhotic and biliary cirrhotic livers using two‐dimensional electrophoretograms of [35S] methionine‐labeled translational products of total hepatic RNA and RNA/DNA hybridization. α1‐antitrypsin precursor product was identified by immunoprecipitation. The relative abundance of α1‐antitrypsin product from normal (0.989 ± 0.197), cirrhotic (0.956 ± 0.062) and α1‐antitrypsin deficient (0.818 ± 0.12) livers was not significantly different. Although (RNA/DNA) was decreased in the PiZZ cirrhotic livers compared to normal (0.56 ± 0.045 vs. 0.95 ± 0.225), it equaled that found in the PiM cirrhotic livers (0.56 ± 0.055). The concentration of α1‐antitrypsin mRNA [relative abundance × (RNA/DNA)], while decreased in PiZZ compared to normal liver, is thus no different in PiZZ cirrhotics than in PiM cirrhotics. We confirmed this observation by quantitation of the α1‐antitrypsin mRNA using an α1‐antitrypsin genomic probe. By RNA/DNA hybridization, α1‐antitrypsin mRNA was equal in PiM cirrhotic and PiZZ cirrhotic (38.48 ± 4.5 vs. 31.93 ± 2.1), but significantly decreased from noncirrhotic PiM liver (58.36 ± 12.7). We conclude that α1‐antitrypsin mRNA is decreased in cirrhosis of any etiology, and this decrease appears to represent a general response of the liver to injury. Since the decreased α1‐antitrypsin mRNA in PiM cirrhotics is associated with normal serum α1‐antitrypsin levels, it is unlikely that the decreased α1‐antitrypsin mRNA in PiZZ cirrhotics accounts for their decreased serum levels.

AB - We quantitated α1‐antitrypsin mRNA in normal, α1‐antitrypsin‐deficient cirrhotic and biliary cirrhotic livers using two‐dimensional electrophoretograms of [35S] methionine‐labeled translational products of total hepatic RNA and RNA/DNA hybridization. α1‐antitrypsin precursor product was identified by immunoprecipitation. The relative abundance of α1‐antitrypsin product from normal (0.989 ± 0.197), cirrhotic (0.956 ± 0.062) and α1‐antitrypsin deficient (0.818 ± 0.12) livers was not significantly different. Although (RNA/DNA) was decreased in the PiZZ cirrhotic livers compared to normal (0.56 ± 0.045 vs. 0.95 ± 0.225), it equaled that found in the PiM cirrhotic livers (0.56 ± 0.055). The concentration of α1‐antitrypsin mRNA [relative abundance × (RNA/DNA)], while decreased in PiZZ compared to normal liver, is thus no different in PiZZ cirrhotics than in PiM cirrhotics. We confirmed this observation by quantitation of the α1‐antitrypsin mRNA using an α1‐antitrypsin genomic probe. By RNA/DNA hybridization, α1‐antitrypsin mRNA was equal in PiM cirrhotic and PiZZ cirrhotic (38.48 ± 4.5 vs. 31.93 ± 2.1), but significantly decreased from noncirrhotic PiM liver (58.36 ± 12.7). We conclude that α1‐antitrypsin mRNA is decreased in cirrhosis of any etiology, and this decrease appears to represent a general response of the liver to injury. Since the decreased α1‐antitrypsin mRNA in PiM cirrhotics is associated with normal serum α1‐antitrypsin levels, it is unlikely that the decreased α1‐antitrypsin mRNA in PiZZ cirrhotics accounts for their decreased serum levels.

UR - http://www.scopus.com/inward/record.url?scp=0023037453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023037453&partnerID=8YFLogxK

U2 - 10.1002/hep.1840060605

DO - 10.1002/hep.1840060605

M3 - Article

C2 - 2431990

AN - SCOPUS:0023037453

VL - 6

SP - 1252

EP - 1258

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -